移植前FDG PET/CT对R-DHAC挽救化疗后DLBCL的预后价值
该回顾性分析纳入62例接受R-DHAC挽救化疗后、移植前进行FDG PET/CT的难治/复发弥漫大B细胞淋巴瘤患者,采用Deauville评分和总病灶糖酵解(TLG)评估。
要点
- 移植前Deauville评分5分提示PFS较短,4分不预测结局。
- 仅移植前TLG与PFS和OS均显著相关。
- TLG值得在前瞻性研究中进一步验证。
核心结论
- 移植前Deauville评分5分与较短PFS相关,4分无预后价值。
- 仅移植前TLG与PFS和OS均显著相关。
研究设计与样本
- 回顾性分析62例接受R-DHAC挽救化疗后、移植前行FDG PET/CT的难治/复发弥漫大B细胞淋巴瘤患者。
- 采用Deauville评分和总病灶糖酵解(TLG)评估PET/CT。
主要发现
- Deauville评分4分不预测结局。
关键数值与推荐
- Deauville评分4分:不预测结局。
临床怎么用
- 对R-DHAC挽救化疗后拟移植的rrDLBCL患者,可结合移植前PET/CT的Deauville评分5分和TLG评估预后。
局限性
- 样本量较小(62例),为回顾性分析。
- TLG的预后价值需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) who had pre-transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R-DHAC (rituximab, dexamethasone, high-dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pre-transplantation PET/CT with Deauville score of 5 was associated with shorter progression-free survival (PFS) (P = 0·01), while a Deauville score of 4 was not predictive of outcome. Only pre-transplant TLG was significantly associated with both PFS (P = 0·005) and overall survival (P = 0·03). TLG deserves to be further investigated in prospective studies.
引用
- Mesguich C, Roch A, Hindié E, et al. Prognostic utility of pre-transplantation [18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy. Br J Haematol. 2019. PMID: 31388998. doi:10.1111/bjh.16144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。